Formulation Development
Pancreatic Cancer Phase 2a Study With Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Can-Fite BioPharma Ltd. recently announced that it achieved the over 50% enrollment milestone in its Phase 2a trial of Namodenoson for pancreatic cancer. The Phase…
Incannex Reports Positive Topline Results From RePOSA Phase 2 Trial of IHL-42X
Incannex Healthcare Inc. recently announced positive topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep…
FDA Provides Trethera Clearance to Initiate Clinical Trial in Healthy Volunteers to Study Food Effect & Biomarkers
Trethera Corporation recently announced the US FDA has cleared a clinical trial evaluating its novel drug, TRE-515, in healthy volunteers. TRE-515, a clinical-stage drug in…
Merck Advances Neuroscience Pipeline With Novel Therapies in Phase 2 Studies for Treatment of Alzheimer’s Disease
Merck, known as MSD outside of the US and Canada, a premier research-intensive biopharmaceutical company, is initiating two Phase 2 clinical studies for MK-2214 and…
Ofichem Expands Drug Substance Capabilities With Acquisition of Meribel Pharma Solutions’ Uppsala Site in Sweden
Ofichem recently announced the acquisition of Meribel Pharma Solutions’ site in Uppsala, Sweden. This strategic step enhances Ofichem’s ability to support early phase, IP-driven drug…
Centauri Therapeutics Receives an Additional $5.1 Million From CARB-X to Progress ABX-01 Lead Compound to First-in-Human Clinical Trials
Centauri Therapeutics Limited recently announced CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1 million in funding for the development of their lead…
BriaPro Therapeutics Files Patent Application for Immuno-Oncology Platform With Novel Multitargeting Agents
BriaCell Therapeutics Corp. and its majority owned subsidiary, BriaPro Therapeutics Corp., recently announce BriaPro is developing novel multivalent agents for cancer treatment. BriaPro has filed…
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
Therini Bio, Inc. recently announced the first patient has been dosed in a Phase 1b trial evaluating THN391 for the treatment of Alzheimer's disease (AD).…
Veranova Appoints New Vice President of Bioconjugation
Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, is pleased….
Breakthrough Study From UCLA Demonstrates Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
Can-Fite BioPharma Ltd. recently announced a leading group from University of Los Angeles (UCLA) demonstrates that Piclidenoson showed efficacy in an experimental model of vascular…
LENZ Therapeutics Announces NMPA Submission of ND for LNZ100 for Presbyopia Treatment
LENZ Therapeutics, Inc. recently announced CORXEL Pharmaceuticals has submitted the New Drug Application (NDA) for LNZ100 to the Center for Drug Evaluation (CDE) of the…
Radiopharm Theranostics Receives IND Approval to Initiate Phase 1 Therapeutic Clinical Study to Target B7H3 With Betabart
Radiopharm Theranostics recently announced the US FDA has provided clearance of the Company’s Investigational New Drug (IND) application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody…
Deciphera Announces Positive CHMP Opinion for ROMVIMZA for the Treatment of Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, LLC and Ono Pharmaceutical Co., Ltd. recently announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…
Inmagene Biopharmaceuticals Announces Completion of Merger With Ikena Oncology & Concurrent Private Placement of $75 Million
Inmagene Biopharmaceuticals recently announced the completion of its previously announced merger with Ikena Oncology, Inc. The combined company will operate under the name ImageneBio, Inc.…
Simtra BioPharma Solutions Announces Strategic Purchase to Expand US Manufacturing Capacity for Injectable Medicines
Simtra BioPharma Solutions recently announced the purchase from Cook Group of a 65-acre property (301 N. Curry Pike) with more than 300,000 square feet of…
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Candel Therapeutics, Inc. recently announced the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This…
Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva & Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care
Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with US rheumatologists now treating close to 40% of their moderate-to-severe patients with biologics. Most…
Jupiter Neurosciences Highlights Critical Advancement of JOTROL Over Traditional Resveratrol With Breakthrough Bioavailability & CNS-Targeted Science
Jupiter Neurosciences, Inc. spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL, over conventional resveratrol formulations. Resveratrol is one of the world’s most…
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas Wearable Injector Technology for Biologic Drugs
BD (Becton, Dickinson and Company) recently announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for subcutaneous delivery of complex…
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences, Inc. recently announced the US FDA has granted Breakthrough Therapy designation to delpacibart zotadirsen (del-zota) for the treatment of Duchenne muscular dystrophy (DMD)…
